• Molecular NameCinnarizine
  • SynonymNA
  • Weight368.524
  • Drugbank_IDDB00568
  • ACS_NO298-57-7
  • Show 2D model
  • LogP (experiment)5.63
  • LogP (predicted, AB/LogP v2.0)5.44
  • pkaN/A
  • LogD (pH=7, predicted)4.36
  • Solubility (experiment)0.75 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-3.53
  • LogSw (predicted, AB/LogsW2.0)0.06
  • Sw (mg/ml) (predicted, ACD/Labs)0.05
  • No.of HBond Donors0
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds6
  • TPSA6.48
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn anti-histaminic drug which is mainly used for the control of vomiting due to motion sickness.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmThe main paths of cinnarizine metabolism in humans are aromatic hydroxylation in benzhydryl and cinnamyl groups and dealkylation of piperazine nitrogen atoms.
  • Half life5 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A